TITLE

Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial

AUTHOR(S)
Arabi, Yaseen M.; Aljumah, Abdulrahman; Dabbagh, Ousama; Tamim, Hani M.; Rishu, Asgar H.; Al-Abdulkareem, Abdulmajeed; Al Knawy, Bandar; Hajeer, Ali H.; Tamimi, Waleed; Cherfan, Antoine
PUB. DATE
December 2010
SOURCE
CMAJ: Canadian Medical Association Journal;12/14/2010, Vol. 182 Issue 18, p1971
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Recent studies have reported a high prevalence of relative adrenal insufficiency in patients with liver cirrhosis. However, the effect of corticosteroid replacement on mortality in this high-risk group remains unclear. We examined the effect of low-dose hydrocortisone in patients with cirrhosis who presented with septic shock. Methods: We enrolled patients with cirrhosis and septic shock aged 18 years or older in a randomized double-blind placebo-controlled trial. Relative adrenal insufficiency was defined as a serum cortisol increase of less than 250 nmol/L or 9 µg/dL from baseline after stimulation with 250 µg of intravenous corticotropin. Patients were assigned to receive 50 mg of intravenous hydrocortisone or placebo every six hours until hemodynamic stability was achieved, followed by steroid tapering over eight days. The primary outcome was 28-day all-cause mortality. Results: The trial was stopped for futility at interim analysis after 75 patients were enrolled. Relative adrenal insufficiency was diagnosed in 76% of patients. Compared with the placebo group (n = 36), patients in the hydrocortisone group (n = 39) had a significant reduction in vasopressor doses and higher rates of shock reversal (relative risk [RR] 1.58, 95% confidence interval [CI] 0.98-2.55, p = 0.05). Hydrocortisone use was not associated with a reduction in 28-day mortality (RR 1.17, 95% CI 0.92-1.49, p = 0.19) but was associated with an increase in shock relapse (RR 2.58, 95% CI 1.04-6.45, p = 0.03) and gastrointestinal bleeding (RR 3.00, 95% CI 1.08-8.36, p = 0.02). Interpretation: Relative adrenal insufficiency was very common in patients with cirrhosis presenting with septic shock. Despite initial favourable effects on hemodynamic parameters, hydrocortisone therapy did not reduce mortality and was associated with an increase in adverse effects.
ACCESSION #
57855158

 

Related Articles

  • Effect of Triglycyl--Lysin--Vasopressin on Quantitative Liver Function Tests in Patients with Cirrhosis. Merkel, Carlo; Bianco, Simone; Bolognesi, Massimo; Caregaro, Lorenza; Amodio, Piero; Sacerdoti, David; Gatta, Angelo // American Journal of Gastroenterology;Nov1992, Vol. 87 Issue 11, p1580 

    The effects of vasopressin and of its analogues on liver function, and their possible mechanisms of action, are poorly understood. This study was designed to assess the effect of triglycyl-lysin-vasopressin on liver function, evaluated by two quantitative tests independent of liver blood flow,...

  • Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis. Combes, Burton; Luketic, Velimir A.; Peters, Marion G.; Zetterman, Rowen K.; Garcia-Tsao, Guadalupe; Munoz, Santiago J.; Lin, Danyu; Flye, Nancy; Carithers, Robert L. // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p264 

    OBJECTIVE: Randomized, double-blind, placebo-controlled trials of ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) have not demonstrated improvement in survival during the placebo-controlled phases of these trials. Analyses purporting to demonstrate a survival...

  • A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. Sharma, Barjesh Chander; Sharma, Praveen; Lunia, Manish Kumar; Srivastava, Siddharth; Goyal, Rohit; Sarin, S K // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1458 

    OBJECTIVES:Hepatic encephalopathy (HE) is associated with poor prognosis in cirrhosis. Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have shown to be effective in HE. We evaluated the efficacy and safety of...

  • Liver cirrhosis.  // Nursing Standard;11/22/2006, Vol. 21 Issue 11, p58 

    A quiz concerning liver cirrhosis is presented.

  • Impact of bolus application of low-dose hydrocortisone on glycemic control in septic shock patients. Weber-Carstens, Steffen; Deja, Maria; Bercker, Sven; Dimroth, Anna; Ahlers, Olaf; Kaisers, Udo; Keh, Didier // Intensive Care Medicine;Apr2007, Vol. 33 Issue 4, p730 

    To determine whether glycemic control is less feasible when hydrocortisone is given as a bolus compared with continuous application in septic shock patients. Observational prospective pilot study. Fourteen-bed surgical university hospital ICU. Sixteen consecutive patients with septic shock...

  • Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrinedependent septic.  // Critical Care;2011, Vol. 15 Issue 3, p10453 

    The article presents a study on the effects of continuously infused norepinephrine (NE) with terlipressin (TP), arginine vasopressin (AVP), or placebo on sublingual microcirculation in septic shock patients. The study uses a prospective, randomized, double-blind clinical trial. Results show that...

  • Liver cirrhosis: lobar differences in disease progression and carcinogenesis. Sakon, Masato // Journal of Gastroenterology;2000, Vol. 35 Issue 6, p479 

    Comments on a study by S. Arjizumi et al on lobar differences in liver disease progression and carcinogenesis. Factors that influence differences in progression of liver cirrhosis among liver segments; Segment where hepatocellular carcinoma occurs frequently; Role of blood flow in hypertrophy...

  • Type 1 diabetes associated with chronic liver disease. Taliercio, Adam // Endocrine Today;Dec2012, Vol. 10 Issue 12, p11 

    The article explores a study on patient with type 1 diabetes' greater risk for developing chronic liver disease, which was concluded by the researchers after they found that 14 type 1 diabetes patients in their study developed cirrhosis.

  • Liver I.  // Gut;Jun2014 Supplement, Vol. 63, pA87 

    The article presents abstracts on studies done on liver diseases on topics including reduced amount of serum sodium in patients treated with terlipressin, care in decompensated cirrhosis, and management of patients with decompensated liver disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics